Home › Research › Down syndrome and Alzheimer's
Beta-amyloid protein probe hybridized to chromosome 9 in 3 Alzheimer disease individuals
Jenkins EC, Devine-Gage EA, Yao XL, Houck GE, Brown WT, Robakis NK, Wisniewski KE, Silverman WP et al.. Progress in clinical and biological research, 1989-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We have reported recently the sublocalization of an Alzheimer Disease-associated gene that encodes for cerebrovascular beta-amyloid protein (BAP). Its locus appears to be at or proximal to band 21q2105 through band 21q11.1. We have also observed hybridization to chromosome 20 in normal and Down syndrome individuals using the single-stranded form of the probe. Further, we have found that BAP hybridizes to chromosome 9 in lymphoblastoid cells from three individuals from two families with familial Alzheimer Disease (AD). We have now obtained additional data which shows significant hybridization to chromosomes 9,20 and 21 for two normal control individuals, a Down syndrome (DS) individual and three AD individuals. When the normal and Down Syndrome individuals were compared to the group of individuals with AD, significant hybridization to chromosome 9 occurred in the Alzheimer group only (p less than .05). Almost half of the silver grains on chromosome 9 in the three AD individuals were localized to the distal area of the long arm. Whether these observations demonstrate an apparent genetic marker in these three individuals with familial AD, or whether our observations have identified a marker for both familial and sporadic AD will be determined by further studies.
What this study adds
Evidence grade: Low
This early laboratory study found that a beta-amyloid protein probe hybridized to chromosome 9 in three people with familial Alzheimer's disease but not in normal or Down syndrome individuals. The authors state further studies are needed to determine whether this is a genetic marker, so it has no current treatment or prevention meaning.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jenkins, E. C., Devine-Gage, E. A., Yao, X. L., Houck, G. E., Brown, W. T., Robakis, N. K., et al. (1989). Beta-amyloid protein probe hybridized to chromosome 9 in 3 Alzheimer disease individuals. Progress in clinical and biological research.
Vancouver
Jenkins EC, Devine-Gage EA, Yao XL, Houck GE, Brown WT, Robakis NK, et al. Beta-amyloid protein probe hybridized to chromosome 9 in 3 Alzheimer disease individuals. Progress in clinical and biological research. 1989. PMID: 2690102.
BibTeX
@article{jenkins1989-2690102,
author = {Jenkins, E. C. and Devine-Gage, E. A. and Yao, X. L. and Houck, G. E. and Brown, W. T. and Robakis, N. K. and Wisniewski, K. E. and Silverman, W. P. and others},
title = {{Beta-amyloid protein probe hybridized to chromosome 9 in 3 Alzheimer disease individuals}},
journal = {Progress in clinical and biological research},
year = {1989},
pmid = {2690102}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We have now obtained additional data which shows significant hybridization to chromosomes 9,20 and 21 for two normal control individuals, a Down syndrome (DS) individual and three AD individuals.
- When the normal and Down Syndrome individuals were compared to the group of individuals with AD, significant hybridization to chromosome 9 occurred in the Alzheimer group only (p less than .05).
Why it matters
This early laboratory study found that a beta-amyloid protein probe hybridized to chromosome 9 in three people with familial Alzheimer's disease but not in normal or Down syndrome individuals. The authors state further studies are needed to determine whether this is a genetic marker, so it has no current treatment or prevention meaning.
Study details
- Evidence strengthLow
How this study scored 25/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 24 of the 96 points we could judge it on, which is 25 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Progress in clinical and biological research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1989 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 39 year(s) since 1989 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Henryk M. Wı́sniewski: h-index 76 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | New York State Office for People With Developmental Disabilities: institution h-index 138 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 2690102) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 24 of the 96 points we could judge it on is 25 out of 100. |
| Total | 25 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.